staphylococcus epidermidis
Staphylococcus epidermidis is a Gram-positive bacterium, and one of over 40 species belonging to the genus Staphylococcus. It is part of the normal human microbiota, typically the skin microbiota, and less commonly the mucosal microbiota and also found in marine sponges. It is a facultative anaerobic bacteria. Although S. epidermidis is not usually pathogenic, patients with compromised immune systems are at risk of developing infection. These infections are generally hospital-acquired. S. epidermidis is a particular concern for people with catheters or other surgical implants because it is known to form biofilms that grow on these devices. Being part of the normal skin microbiota, S. epidermidis is a frequent contaminant of specimens sent to the diagnostic laboratory. — Wikipedia
Clinical trial activity
3 trials · 3 clinical orgs · 0 marketing orgs
Earliest trial started Jan 21, 2019 (NCT03820076)
Timeline
2020s
- Jan 1, 2024
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
- microbiotaTissue restoration
microbiota tissue restoration
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Sources
- WikipediaStaphylococcus epidermidis ↗
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06830863 | Phase 1/Phase 2 (Phase 2) | Mar 14, 2025 | Azitra Inc., Prosoft Clinical |
| NCT04731259 | Phase 1/Phase 2 (Phase 2) | Jan 31, 2024 | Azitra Inc. |
| NCT03820076 | N/A | Jan 21, 2019 | Azitra Inc., RCTS, Inc. |
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Azitra Inc. | For profit | 3 | 3 | 2 | 2019 |
| Prosoft Clinical | For profit | 1 | 0 | 1 | 2025 |
| RCTS, Inc. | For profit | 1 | 0 | 1 | 2019 |